Takeda Adds Celiac Disease Candidate To GI Efforts

Phase II Study Shows Antigen-Specific Immune Tolerance Is Possible In Autoimmune Diseases

Takeda has exercised an option on partner Cour Pharmaceutical’s first-in-class lead product, after a positive Phase IIa study showed, for the first time, it was possible to induce specific immune tolerance to a foreign antigen in an autoimmune disease.    

Wheat
Gluten in wheat causes difficulties for celiac patients • Source: Shutterstock

Four years after first partnering with the US biotech, Cour Pharmaceutical Development Co. Inc., the Osaka, Japan-based multinational, Takeda Pharmaceutical has acquired an exclusive global license to develop and commercialize Cour’s lead product, CNP-101/TAK-101, for the treatment of celiac disease.

The deal is important because there are no treatment options for celiac disease patients other than attempting to control symptoms...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.